These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32392378)

  • 1. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
    Liu S; Zhang X; Jiang Q; Liang T
    FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
    Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
    Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
    Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
    Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
    Wang J; Xu Y; Zhao H; Zhang X
    J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
    Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
    Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
    Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.
    Hirasawa Y; Kohno N; Yokoyama A; Kondo K; Hiwada K; Miyake M
    Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):589-94. PubMed ID: 10673204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.
    Atzin-Méndez JA; López-González JS; Báez R; Arenas-Del Angel MC; Montaño LF; Silva-Adaya D; Lascurain R; Gorocica P
    Oncol Rep; 2016 Jan; 35(1):33-42. PubMed ID: 26498650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
    Liang T; Han Z; Zhao H; Zhang X; Wang Y
    Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
    Du KL; Ji WT; Jiang QH; Wang Y
    Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
    Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
    Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.
    Guan S; Liu B; Zhang C; Lee KH; Sun S; Wei J
    Clin Transl Oncol; 2013 Oct; 15(10):825-9. PubMed ID: 23423807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Circulating CD4
    Hu X; Gu Y; Zhao S; Hua S; Jiang Y
    Cancer Biother Radiopharm; 2019 Jun; 34(5):325-333. PubMed ID: 30925076
    [No Abstract]   [Full Text] [Related]  

  • 15. Altered levels of circulating natural antibodies against VEGFR1-derived peptide in atherosclerosis.
    Wang P; Liu S; Wang Z; Zhao H; Zhang X
    J Int Med Res; 2020 Aug; 48(8):300060520948750. PubMed ID: 32811267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of Circulating Natural Antibodies Against CD25 and FOXP3 in Type-2 Diabetes.
    Qiu C; Li C; Wu X; Chen X; Zhang X; Meng Q
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
    Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
    Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
    Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
    Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
    Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
    Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
    Laidi F; Bouziane A; Errachid A; Zaoui F
    Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.